EyePoint Inc EYPT
News
-
EYPT SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving EyePoint Pharmaceuticals
-
EyePoint Pharmaceuticals Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into EyePoint Pharmaceuticals (EYPT)
-
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT
-
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT
-
These beaten-down stocks could bounce back in January, if history is any guide
-
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT
-
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT
-
Investigation Alert: EyePoint, Inc. (EYPT) Investors are Encouraged to Contact Kessler Topaz Meltzer & Check, LLP
Trading Information
- Previous Close Price
- $0.41
- Day Range
- $0.39–0.44
- 52-Week Range
- $0.39–19.11
- Bid/Ask
- $0.42 / $0.42
- Shares Outstanding
- 86.21M
- Market Cap
- $37.07M
- Volume/Avg
- 32M / 8M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 12.56
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 214
- Website
- https://www.eyepoint.bio
Valuation
|
Metric
|
EYPT
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.22 |
Price/Sales | 12.56 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
EYPT
|
|---|---|
Quick Ratio | 4.30 |
Current Ratio | 4.50 |
Interest Coverage | — |
Quick Ratio
EYPT
Profitability
|
Metric
|
EYPT
|
|---|---|
Return on Assets (Normalized) | −97.27% |
Return on Equity (Normalized) | −121.31% |
Return on Invested Capital (Normalized) | −114.55% |
Return on Assets
EYPT
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|sGT>K&r | LOCK|!&#j! | $133B | |||
| Moderna Inc
MRNA
| LOCK|vLlCNb | LOCK|!? | $98B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|vh?Z^YS | LOCK|Y?rh | $83B | |||
| argenx SE ADR
ARGX
| LOCK|f^Jx?G> | LOCK|?Fd | $56B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|&>F^$$ | LOCK|g>F | $45B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|fdpzP% | LOCK|^^hl! | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|hT?C^^?@ | LOCK|#&Ct^ | $28B | |||
| Incyte Corp
INCY
| LOCK|Cv^Ck# | LOCK|#cv | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|?&vg&$ | LOCK|<^ | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|<l^tnb# | LOCK|<m | $14B |
United States